Blood proteins may predict success of gMG treatments
Measuring changes in blood levels of two proteins — neurofilament light chain (NfL) and calprotectin (CLP) — may show how well people with generalized myasthenia gravis (gMG) respond to Ultomiris (ravulizumab) and Vyvgart (efgartigimod). That’s according to a small, real-world study in Germany that found that rising…